Drug Derived from Ticks Could Take Bite Out of Pain
/By Pat Anson, PNN Editor
If you’ve experienced Lyme disease, probably the last place you’d look for pain relief is ticks. The insects are notorious for spreading Lyme, a bacterial illness that causes chronic fatigue, muscle and joint pain, cognitive issues and other symptoms that can last for years.
But UK researchers say a protein found in tick saliva – called Votucalis – shows potential as a treatment for chronic pain. In experiments on laboratory animals, Votucalis provided pain and itch relief to mice subjected to neuropathic pain. Their findings were recently published in the journal Frontiers in Pharmacology.
“It is amazing that a protein found in the saliva of this tiny creature could prevent chronic pain and itching in people,” says co-author Ilona Obara, PhD, Director of Research in the School of Pharmacy at Newcastle University. “These are conditions that bring a huge amount of misery, and current medication displays limited efficacy, and can also often be detrimental to patients.
“Votucalis has already been tested in humans with other conditions, including conjunctivitis, without major side-effects, so the potential for this to be developed into a drug to tackle chronic pain and itching is definitely there.”
Obara began her research at Durham University with co-author Paul Chazot, PhD. Their research focused on tick saliva because it has pain relieving, anti-inflammatory and anti-coagulant effects on mammals. Ticks are parasitic blood feeders that rely on their “hosts” to be unaware that they have uninvited dinner guests.
Researchers found that Votucalis is particularly good at binding to histamine and preventing it from activating histamine cell receptors, resulting in reduced itching and pain sensations when a host animal is bitten.
“Our study is the first to show evidence of the anti-itch and pain relief potential of Votucalis, which is very exciting. We could be on the brink of discovering a viable alternative to opioid and gabapentinoid drugs,” said Chazot, an Associate Professor in the Department of Biosciences at Durham University.
The next step is to develop a drug delivery system to effectively administer Votucalis at the site of itch and pain. The research is being funded by the government of Saudi Arabia – where ticks are emerging as a public health problem -- and Akari Therapeutics, a pharmaceutical company that hopes to turn Votucalis into a treatment for neuropathic and inflammatory pain.
Unlike opioids, Votucalis does not enter the brain, which means it is not addictive and less likely to cause side effects.
“We are delighted to be working with Drs. Chazot and Obara on the pipeline drug Votucalis. The exciting new data in pain and itch supports the potential that the unique mode of action of Votucalis, inhibiting all four histamine receptors, opens exciting therapeutic opportunities in pain management and dermatology," Clive Richardson, CEO of Akari Therapeutics, said in a statement.
Akari is developing another drug derived from ticks – called nomacopan – for the treatment of a rare skin disease and ophthalmic conditions in the eye.
